Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7,134 INR | -0.14% | -5.39% | +34.93% |
May. 10 | Neuland Laboratories' Consolidated Profit Declines in Fiscal Q4 | MT |
May. 10 | Neuland Laboratories Limited Recommends Final Dividend for the Financial Year 2023-24 | CI |
Sales 2024 | 15.59B 187M | Sales 2025 * | 16.39B 196M | Capitalization | 91.53B 1.1B |
---|---|---|---|---|---|
Net income 2024 | 3B 35.93M | Net income 2025 * | 3.19B 38.17M | EV / Sales 2024 | 5.17 x |
Net cash position 2024 * | 2.32B 27.84M | Net cash position 2025 * | 4.33B 51.85M | EV / Sales 2025 * | 5.32 x |
P/E ratio 2024 |
26.9
x | P/E ratio 2025 * |
28.9
x | Employees | 1,554 |
Yield 2024 * |
0.17% | Yield 2025 * |
0.14% | Free-Float | 61.98% |
Latest transcript on Neuland Laboratories Limited
1 day | -0.14% | ||
1 week | -5.39% | ||
Current month | -6.14% | ||
1 month | +7.11% | ||
3 months | +10.75% | ||
6 months | +33.43% | ||
Current year | +34.93% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 01-12-31 | |
Abhijit Majumdar
DFI | Director of Finance/CFO | - | 22-11-22 |
Chief Tech/Sci/R&D Officer | - | Nov. 21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 22-10-30 | |
Director/Board Member | 80 | 19-02-11 | |
Sugata Sircar
BRD | Director/Board Member | 60 | 23-06-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 7,134 | -0.14% | 972 |
24-05-09 | 7,144 | -4.07% | 1,069 |
24-05-08 | 7,447 | +1.24% | 1,147 |
24-05-07 | 7,356 | -1.48% | 1,003 |
24-05-06 | 7,466 | -0.99% | 1,433 |
Delayed Quote Bombay S.E., May 10, 2024 at 06:00 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+34.93% | 1.1B | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- NEULANDLAB Stock